News in brief: Wider PBS listing for nusinersen; Nitrous oxide ‘nangs’ misuse leads to myelo-neuropathy; Choosing Wisely for COVID-19

Nusinersen: wider PBS listing recommended The Pharmaceutical Benefits Advisory Committee has recommended extending the existing PBS listing of nusinersen (Spinraza) to include the treatment of all paediatric patients with Type III Spinal muscular atrophy (SMA) who have symptom onset prior to 18 years of age. At its July meeting the PBAC said this would provide ...

Already a member?

Login to keep reading.

© 2021 the limbic